Edgar Filing: Clovis Oncology, Inc. - Form 4

Clovis O Form 4	ncology, Inc.										
June 14,	2013										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION									PPROVAL		
Washington, D.C. 20549								N OMB Number:	3235-0287		
Check this box if no longer								Expires:	January 31, 2005		
subject to Section 16. Form 4 or						ICIAL	OWNERSHIP OF	Estimated burden hou response	average urs per		
may	continue. Instruction	(a) of the l	Public U		ding Cor	npany A	hange Act of 1934, .ct of 1935 or Secti f 1940				
(Print or T	ype Responses)										
	and Address of Reporting	2. Issuer Name and Ticker or Trading Symbol Clovis Oncology, Inc. [CLVS]				5. Relationship of Reporting Person(s) to Issuer					
(Last)) (First) (Middle)			_		(Check all applicable)				
C/O VE	RSANT VENTURE HILL ROAD, BLDG	3. Date of Earliest Transaction (Month/Day/Year) 06/13/2013				X_ Director 10% Owner Officer (give title Other (specify below) below)					
SUILE			4 10 4			1			(2)		
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person					
MENLO	D PARK, CA 94025					Form filed by More than One Reporting Person					
(City)) (State)	(Zip)	Tal	ble I - Non-l	Derivative	Securities	s Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Date 2A. Deemed ar) Execution Date, if any (Month/Day/Year)		Code	4. Securit onAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Pri	ce (Instr. 5 and 4)				
Reminder:	Report on a separate line	e for each cl	ass of sec	curities bene	ficially ow	ned directl	ly or indirectly.				
Persons who respond to the collect information contained in this form a required to respond unless the form displays a currently valid OMB cont number.							n are not orm	SEC 1474 (9-02)			
	Tab						or Beneficially Owned le securities)	d			
			0.1 F								

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D

Edgar Filing: Clovis Oncology, Inc. - Form 4

Security (Instr. 3)	or Exercise any Price of (Month/Day, Derivative Security		th/Day/Year)	Code (Instr. 8)	Securities Acquired or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	(Month/Day/Year)		(Instr. 3 and 4)		9 (
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 71.11	06/13/2013		А	12,414		<u>(1)</u>	06/13/2023	Common Stock	12,414	
Reporting Owners											
Reporting Owner Name / Address			Relationships								
	DDDIANC		Dire	ector 109	% Owner	Offic	er Other				
ATWOOD BRIAN G C/O VERSANT VENTURES 3000 SAND HILL ROAD, BLDG 4, SUITE 210 MENLO PARK, CA 94025		2 2 1 0	X								
Signa	tures										
/s/ Brian Atwood	G.	06/13/2013									

**Signature of Date Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.